Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies

Li-Ping Zhao; Jun-Hu Hu; Die Hu; Hao-Jie Wang; Chang-Gang Huang; Ru-Hua Luo; Zhao-Huang Zhou; Xin-Yun Huang; Tian Xie; Jian-Shu Lou

doi:10.1016/j.biopha.2022.112949

Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies

Biomed Pharmacother. 2022 Jun:150:112949. doi: 10.1016/j.biopha.2022.112949. Epub 2022 Apr 18.

Authors

Affiliations

¹ School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
² Department of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA. Electronic address: xyhuang@med.cornell.edu.
³ School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China. Electronic address: tianxie@hznu.edu.cn.
⁴ School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China. Electronic address: jlouab@connect.ust.hk.

PMID: 35447545
DOI: 10.1016/j.biopha.2022.112949

Abstract

Immunotherapy is now a mainstay in cancer treatments. Programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) therapies have opened up a new venue of advanced cancer immunotherapy. However, hyperprogressive disease (HPD) induced by PD-1/PD-L1 inhibitors caused a significant decrease in the overall survival (OS) of the patients, which compromise the efficacy of PD-1/PD-L1 inhibitors. Therefore, HPD has become an urgent issue to be addressed in the clinical uses of PD-1/PD-L1 inhibitors. The mechanisms of HPD remain unclear, and possible predictive factors of HPD are not well understood. In this review, we summarized the potential mechanisms of HPD and coping strategies that can effectively reduce the occurrence and development of HPD.

Keywords: Biomarkers; Cancer immunotherapy; Coping strategies; HPD; PD-1/PD-L1 inhibitors.

Publication types

Review

MeSH terms

Adaptation, Psychological
Disease Progression
Humans
Immune Checkpoint Inhibitors* / therapeutic use
Immunotherapy
Programmed Cell Death 1 Receptor*

Substances

Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor